Pulled from Benzinga Pro data, Medifast (NYSE:MED) posted Q3 earnings of $36.16 million, an increase from Q2 of 7.56%. Sales dropped to $390.40 million, a 13.88% decrease between quarters. In Q2, Medifast earned $39.11 million, and total sales reached $453.33 million.

Why Is ROIC Significant?

Return on Invested Capital is a measure of yearly pre-tax profit relative to capital invested by a business. Changes in earnings and sales indicate shifts in a company's ROIC. A higher ROIC is generally representative of successful growth of a company and is a sign of higher earnings per share in the future. A low or negative ROIC suggests the opposite. In Q3, Medifast posted an ROIC of 31.99%.

Keep in mind, while ROIC is a good measure of a company's recent performance, it is not a highly reliable predictor of a company's earnings or sales in the near future.

For Medifast, the positive return on invested capital ratio of 31.99% suggests that management is allocating their capital effectively. Effective capital allocation is a positive indicator that a company will achieve more durable success and favorable long-term returns.

Upcoming Earnings Estimate

Medifast reported Q3 earnings per share at $3.32/share, which beat analyst predictions of $1.91/share.

This article was generated by Benzinga's automated content engine and reviewed by an editor.